Additional Tofacitinib Efficacy and Safety Data, including Inhibition of Structural Damage, Remission Rates, Patient-Reported Outcomes and Dosing to be Presented
The following data will also be presented:
- A sensitivity analysis of ORAL Scan: “Trimmed Analysis: A New Approach to the Analysis of Sharp Score Data in the Assessment of the Progression of Patients with Rheumatoid Arthritis” [Abstract #26935; Monday, November 12, 2012]
- A post-hoc analysis of radiographic progression in RA patients prone to develop structural damage: “Tofacitinib Inhibits Radiographic Progression in Patients with Rheumatoid Arthritis Prone to Develop Structural Damage: A Post-Hoc Analysis of a Phase 3 Trial” [Abstract #26976; Tuesday, November 13, 2012 at 4:45 p.m. EST]
Additional Efficacy Data
- Prediction of low disease activity: “Tofacitinib And Adalimumab Achieve Similar Rates Of Low Disease Activity In Rheumatoid Arthritis — Lack Of Improvement In Disease Activity Score By 3 Months Predicts Low Likelihood Of Low Disease Activity At 1 Year” (NCT00853385) [Abstract #28067; Monday, November 12, 2012]
- Remission rates: “Remission Rates With Tofacitinib Treatment In Rheumatoid Arthritis: A Comparison Of Various Remission Criteria” [Abstract #27787; Sunday, November 11, 2012 at 3:00 p.m. EST]
- Patient-reported outcomes in ORAL Step and ORAL Scan: “Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate” (NCT00960440 and NCT00847613) [Abstract #27211; Monday, November 12, 2012]
- Dose-related safety and efficacy: “Tofacitinib, An Oral Janus Kinase Inhibitor: Analyses Of Efficacy And Safety Of 10 Versus 5mg Twice Daily In A Pooled Phase 3 And Long-Term Extension Rheumatoid Arthritis Population” [Abstract #26731; Tuesday, November 13 at 2:30 p.m. EST]
- Effects on cholesterol: “Effects Of Tofacitinib On Lipid Profiles And Cholesterol And Lipoprotein Kinetics In Patients With Rheumatoid Arthritis” [Abstract #27669; Monday, November 12, 2012]
- ORAL Sequel vaccine sub-study: “Evaluation Of Influenza And Pneumococcal Vaccine Responses In Patients With Rheumatoid Arthritis Receiving Tofacitinib” (NCT00413699) [Abstract #27391; Monday, November 12, 2012]
- Tuberculosis screening: “Tuberculosis And Tofacitinib Therapy In Patients With Rheumatoid Arthritis” [Abstract #26735, Monday, November 12, 2012]
- Herpes zoster logistic regression analysis: “Herpes Zoster And Tofacitinib Therapy In Patients With Rheumatoid Arthritis” [Abstract #26957; Tuesday, November 13 at 3:45 p.m. EST]
- Meta-analysis of certain side effects: “Meta-Analysis Of Malignancies, Serious Infections, And Serious Adverse Events With Tofacitinib Or Biologic Treatment In Rheumatoid Arthritis Clinical Trials” [Abstract #27741; Monday, November 12, 2012 at 5:15 p.m. EST]
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV